Roche's Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to shortages. Now, Sanofi's rival therapy Kevzara has also been hit by supply constraints.

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumonia ...